Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

Recruiting

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function - CC-220-CP-008

Updated: 26 October, 2021   |   ClinicalTrials.gov

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18-82

    Age Range

  • 3

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Group 1: Participants with severe Renal Impairment (RI)
Drug: Iberdomide
Experimental: Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)
Drug: Iberdomide
Experimental: Group 3: Participants with normal renal function
Drug: Iberdomide

Key Eligibility Criteria

Inclusion Criteria: Inclusion Criteria for All Participants (All Groups) Participants must satisfy the following criteria to be enrolled in the study: 1. Participant is ≥ 18 and ≤ 82 years of age at the time of signing the informed consent form (ICF). 2. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 3. Participant is able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions, the study visit schedule, and other protocol requirements, including contraception requirements. 4. Participant has a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2 at screening. 5. Participant has a body weight > 50 kg at screening. 6. Participant is afebrile (febrile is defined as ≥ 38°C or 100.4°F). Inclusion Criteria for Participants with Severe Renal Impairment (RI) - Group 1 Participants in Group 1 must also satisfy the following criteria to be enrolled in the study: 7. Participant has a supine systolic blood pressure (BP) ≥ 90 and ≤ 180 mm Hg, supine diastolic BP ≥ 60 and ≤ 110 mm Hg, and pulse rate ≥ 40 and ≤ 110 beats per minute. 8. Participant has severe renal impairment as defined by an eGFR < 30 mL/min/1.73 m2 (and not requiring dialysis) at screening. The eGFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation. 9. Participant must be medically stable for at least 1 month before the first IP administration with a clinically acceptable medical history, physical examination (PE), clinical laboratory safety test results, vital sign measurements, and 12-lead electrocardiograms (ECGs) consistent with the underlying stable RI condition, as judged by the Investigator. a. Participant must have a QTcF value < 480 ms. 10. Participant must be stable in concomitant medication regimen (defined as not starting a new medication[s] or a change in the dosage or frequency of the concomitant medication[s] within 7 days or 5 half-lives [whichever is longer] before the first IP administration). Inclusion Criteria for Participants with Kidney Failure on IHD - Group 2 Participants in Group 2 must also satisfy the following criteria to be enrolled in the study: 11. Participant has a pulse rate ≥ 40 and ≤ 110 beats per minute. Blood pressure measurements must be consistent with the participant's underlying medical condition(s) and judged by the Investigator as being clinically acceptable for purposes of study entry. 12. Participant must be medically stable for at least 1 month before the first IP administration with a clinically acceptable medical history, PE, clinical laboratory safety test results, vital sign measurements, and 12-lead ECGs consistent with the underlying kidney failure, as judged by the Investigator. 13. Participant must be stable in concomitant medication regimen 14. Participant has been attending an average of 3 hemodialysis treatments per week within the 3 months prior to screening. Inclusion Criteria for Participants with Normal Renal Function -Group 3 15. Participant has a supine systolic BP ≥ 90 and ≤ 160 mm Hg, supine diastolic BP ≥ 50 and ≤ 100 mm Hg, and pulse rate ≥ 40 and ≤ 100 beats per minute. 16. Participant is in good health, as determined by past medical history, PE, vital signs, 12-lead ECG, and clinical laboratory safety test results, and has normal renal function, as defined by having a Clcr > 90 mL/min estimated using the C-G equation, at screening. 1. If male, participant has a QTcF value < 470 ms; 2. If female, participant has a QTcF value < 480 ms. 17. Participant must match at least 1 participant in Groups 1 or 2 with respect to sex, age (± 10 years), and BMI (± 20%). Exclusion Criteria: Exclusion Criteria for All Participants (All Groups) The presence of any of the following will exclude a participant from enrollment: 1. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study (excluding stable renal impairment and associated comorbidities for participants in Groups 1 and 2). 2. Participant has any condition, including active or uncontrolled infection and/or the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study. 3. Participant has any condition that confounds the ability to interpret data from the study. 4. Participant has any surgical or medical condition(s) possibly affecting drug absorption, distribution, metabolism, or excretion 5. Participant has any medical or dietary conditions affecting assessment of eGFR or creatinine clearance (not applicable for participants in Group 2). 6. Participant is a female of childbearing potential, pregnant, or breastfeeding. 7. Participant has donated blood or plasma within 8 weeks prior to the first IP administration. 8. Participant has a history of alcohol abuse within 6 months prior to the first IP administration, or positive alcohol screen. 9. Participant has history of drug abuse within 6 months prior to the first IP administration, or positive drug screen that is not consistent with the participant's prescribed medication and/or medical history. 10. Participant is known to have serum hepatitis; known to be a carrier of the hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc); have a positive result to the test for hepatitis B or hepatitis C virus (positive viral ribonucleic acid (RNA) titer for hepatitis C) at screening or have a positive result to the test for human immunodeficiency virus (HIV) antibodies at screening. 11. Participant has been exposed to an investigational drug (new chemical entity) within 30 days prior to the first IP administration, or 5 half-lives of that investigational drug, if known (whichever is longer). 12. Participant has consumed any medication known to be a strong CYP3A inducer (including St. John's wort) within 30 days prior to the first IP administration. 13. Participant has consumed any medication known to be a strong CYP3A inhibitor within 7 days prior to the first IP administration. 14. Participant has consumed grapefruit, grapefruit juice, or any other grapefruit-containing product or oranges, orange juice, or any other product containing and/or made from oranges within 7 days prior to the first IP administration. 15. Participant smokes more than 10 cigarettes per day, or the equivalent in other tobacco products (self-reported). 16. Participant is part of the clinical site staff personnel or a family member of the clinical site staff. 17. Participant has received immunization with a live or live attenuated vaccine within 30 days prior the first IP administration or is planning to receive immunization with a live or live attenuated vaccine within 30 days following administration of the last dose of IP. 18. Participant has a history of multiple drug allergies or drug-related anaphylaxis. Exclusion Criteria for Participants with Severe Renal Impairment and Participants with Kidney Failure on IHD - Groups 1 and 2 The presence of any of the following will also exclude a participant from enrollment: 19. Participant has any serious and/or unstable medical condition occurring within 3 months prior to screening (excluding stable renal impairment and associated comorbidities) with complete resolution of any symptoms and no sequelae that would place the participant at a higher risk from receiving IP, based on Investigator assessment in consultation with the Medical Monitor. 20. Participant has any clinically significant laboratory abnormality not related to renal impairment and related complications. 21. Participant has a history of renal transplant. a. Participants who had a renal transplant approximately > 2 years which is no longer functioning are allowable. Exclusion Criteria for Participants with Normal Renal Function - Group 3 The presence of any of the following will also exclude a participant from enrollment: 22. Participant has used any prescribed systemic or topical medication within 30 days prior to the first dose administration. 23. Participant has used any non-prescribed systemic or topical medication within 14 days prior to the first dose administration.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com